Nateglinide

Limits on what this shows

• Key negative/null findings: No study identified reports nateglinide impairing mitochondrial structure, membrane integrity, or biogenesis; the only mitochondrial-channel-specific finding is the reassuring selectivity profile above.
• At-risk subgroups: Not applicable; this is not a depletion or burden finding.
• Counter-evidence on record: This is a pharmacology/electrophysiology comparison, not a clinical cardioprotection outcome trial in nateglinide-treated patients; the clinical significance of preserved ischemic preconditioning was not tested here.

Regulatory status

Not addressed in the DailyMed label as a mitochondrial finding.

Population evidence

Quast U, Stephan D, Bieger S, Russ U. "The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium." Diabetes 2004 (PMID 15561904). Pharmacology comparison across insulin secretagogues including nateglinide; not a clinical outcome trial. Fujitani S, Okazaki K, Yada T, "The ability of a new hypoglycaemic agent, A-4166 [nateglinide's development code], compared to sulphonylureas, to increase cytosolic Ca2+ in pancreatic beta-cells under metabolic inhibition," Br J Pharmacol 1997 (PMID 9105692): cell-based, drug-specific.

Mechanism

KATP channels exist in pancreatic beta cells (target of action) and, as a distinct subtype, in mitochondrial inner membranes of cardiac and vascular tissue (mitoKATP), where their opening during ischemia is cardioprotective. Nateglinide's relative selectivity for the pancreatic (SUR1) channel over cardiac/vascular subtypes and its low mitoKATP activity is the named mechanism for this entry.

Counter-evidence held on record

This entry describes channel-selectivity pharmacology, not a measured effect on mitochondrial energy output in patients. It should not be presented as proof of cardioprotection, only as evidence that nateglinide does not carry the mitoKATP-blocking liability seen with some older sulfonylureas.

Limits on what this shows

• Key negative/null findings: Sawada T et al. 2014 (PMID 24225338) reported improvement in reactive oxygen metabolites in the miglitol arm only, which is relevant null evidence for nateglinide in that comparison. Ju-Ming L et al. 2012 (PMID 22809112) reports no significant effect on hsCRP, so it is not counted here as a demonstrated oxidative-stress benefit. No study found reported an increase in oxidative-stress markers attributable to nateglinide.
• At-risk subgroups: Not applicable; this is not a depletion finding.
• Counter-evidence on record: All identified human studies used active-comparator or single-arm-with-intervention designs; none is a placebo-controlled trial isolating nateglinide from the general benefit of improved glycemic control, so the reduction cannot be fully separated from the drug's intended glucose-lowering effect versus a nateglinide-specific antioxidant action.

Regulatory status

Not addressed in the DailyMed label; oxidative stress is not a labeled adverse effect or monitoring parameter.

Population evidence

Wang L, et al., J Diabetes Res 2013 (PMID 23691521): human, 109 participants with abnormal glucose metabolism, endothelial function and oxidative-stress response to a glucose load with nateglinide intervention. Ju-Ming L, et al., Curr Med Res Opin 2012 (PMID 22809112): human, Chinese type 2 diabetes patients, postprandial glucose, lipid metabolism, oxidative stress, and inflammation with nateglinide. Sawada T, et al., Circ J 2014 (PMID 24225338): human, 104 diabetic patients with coronary artery disease, endothelial dysfunction markers comparing miglitol and nateglinide; the reported improvement in reactive oxygen metabolites occurred in the miglitol arm only, not the nateglinide arm. Verbatim abstract text and precise effect estimates could not be retrieved this session (PubMed's individual article pages did not render through the available fetch tool); direction and cohort composition are drawn from the confirmed search-listing titles and descriptions, not fabricated.

Mechanism

Proposed mechanism is reduction of postprandial glucose excursion itself, which is a recognized driver of glucose-mediated oxidative stress in diabetes; several narrative reviews (Leiter & Lewanczuk 2005, PMID 15691626; Papanas & Maltezos 2009, PMID 19754390) discuss this mechanism at the class level for postprandial glucose regulators including nateglinide.

Cell-based evidence

Sawada F, et al., Metabolism 2008 (PMID 18640379): MIN6 pancreatic beta-cell line, reactive oxygen species and apoptosis measured with nateglinide exposure (Tier B, drug-specific, cell-based).

Counter-evidence held on record

This is not a nutrient or antioxidant-capacity deficiency to correct with supplementation. It describes a reduction in oxidative stress associated with the drug's glucose-lowering action, most likely inseparable from that action rather than an independent antioxidant effect. It should never be presented to a consumer as "nateglinide protects against oxidative stress" in a way that suggests skipping other antioxidant-relevant care.

Limits on what this shows

• Why no grade: Dual condition met: a PubMed search for "nateglinide" AND "copper" returned zero results, and no class-level (meglitinide) copper study was identified either. No circulating consumer claim linking nateglinide to copper status was identified in the sources checked this session (Wikipedia; general literature). A full consumer-content sweep via web search could not be completed this session because the session's general search-tool budget was exhausted before this medication's review began; this is disclosed as a tooling limitation, not asserted as proof no such claim exists anywhere.

Limits on what this shows

• Why no grade: Dual condition met: a PubMed search for "nateglinide" AND "iron" returned zero results. A related finding was located (Skerjanec A, et al., "Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers," J Clin Pharmacol 2010, PMID 19940232) but it studied repaglinide, not nateglinide, and the direction runs the opposite way from a depletion claim: it is the iron chelator deferasirox affecting repaglinide's pharmacokinetics, not the antidiabetic drug affecting iron status. Per the direction-of-interaction rule, this does not support any grade for nateglinide and iron. No circulating consumer claim for nateglinide and iron was identified in the sources checked; a full consumer-content web search could not be completed this session (tooling limitation, see Copper entry).

Limits on what this shows

• Key negative/null findings: None specific to nateglinide; the direction and magnitude of the repaglinide arm's effect in the source study could not be extracted from the available search-listing description this session.
• At-risk subgroups: Not established.
• Counter-evidence on record: This is a class-extrapolation source: repaglinide, not nateglinide, was in the studied cohort, and it is an animal (mouse) model, not a human study. Per Hard Rule, this is Tier C for nateglinide regardless of the source's own rigor.

Regulatory status

Not addressed in the DailyMed label.

Population evidence

Tang Y, Yan M, Fang Z, Jin S, Xu T. "Effects of metformin, saxagliptin and repaglinide on gut microbiota in high-fat diet/streptozocin-induced type 2 diabetic mice." BMJ Open Diabetes Res Care 2024 (PMID 38719505). Repaglinide (a carbamoylmethylbenzoic-acid-derivative meglitinide), not nateglinide (a D-phenylalanine-derivative meglitinide), was the class member studied; a direct nateglinide-and-microbiome PubMed search (multiple phrasings) returned zero results.

Mechanism

Not established for nateglinide specifically. Plausible class-level pathways include altered postprandial glucose excursion and altered gut transit/appetite signaling, but nateglinide's absorption is explicitly meal-composition-independent per its label, which weakens (without ruling out) a direct microbiome mechanism.

Counter-evidence held on record

No probiotic, prebiotic, or gut-support recommendation should be attached to nateglinide on the basis of this entry. It documents a same-class, different-molecule animal finding only, disclosed so a reader does not later encounter a "meglitinides disrupt the microbiome" claim without knowing what was and was not actually tested.

Limits on what this shows

• Why no grade: A PubMed search for nateglinide combined with hemoglobin, hematocrit, anemia, erythropoiesis, and "oxygen delivery" returned 95 results; all reviewed results addressed glycated hemoglobin (HbA1c) as a marker of glycemic control, which per Hard Rule 2 is a clinical-outcome marker, not a measure of oxygen-carrying capacity, red-cell mass, or arterial oxygenation, and must not be filed as an oxygen-delivery finding. No study measuring actual hemoglobin mass, hematocrit, or tissue oxygenation in relation to nateglinide was identified. No circulating consumer claim about nateglinide and oxygen delivery or "energy"/tiredness tied to hemoglobin was identified in the sources checked; a full consumer-content sweep could not be completed this session (tooling limitation, see Copper entry).

Limits on what this shows

• Why no grade: Nateglinide's core pharmacology is built on ATP-sensing: it closes ATP-sensitive potassium (KATP) channels on pancreatic beta cells, a channel whose gating is physiologically regulated by the intracellular ATP/ADP ratio (Fujitani S, et al., Br J Pharmacol 1997, PMID 9105692; Malaisse WJ, Cell Signal 1997, PMID 9218126, class-level glucose-signaling mechanism). Per Hard Rule 2, this is the drug's own intended pharmacologic target mechanism, using ATP as a sensor, and must not be filed as evidence that nateglinide impairs or alters systemic mitochondrial ATP synthesis. No study identified in a dedicated PubMed search (12 results reviewed: drug-impurity analytics, unrelated senescence/exercise research, ghrelin secretion, coagulation/fibrinolysis, EMS protocol content, molecular-docking methods work) measured or reported a change in cellular ATP production attributable to nateglinide. No circulating consumer "low energy/ATP" claim specific to nateglinide was identified in the sources checked; a full consumer-content sweep could not be completed this session (tooling limitation, see Copper entry).